SCHEMBL3035158

SCHEMBL3035158

CNC(=O)[C@H]1CN(c2cc(F)c3nc([S+](C)[O-])sc3c2)C(=O)O1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAOA P21397 5/20 0.38
GRIN1 Q05586 2/20 0.34
GRIN2B Q13224 2/20 0.34
F10 P00742 2/20 0.33
MAPT P10636 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
POLB P06746 3/20 0.32
MAOB P27338 2/20 0.32
GAA P10253 1/20 0.32
ALDH1A1 P00352 1/20 0.31
PKM P14618 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
LMNA P02545 1/20 0.30
PTGS1 P23219 1/20 0.30
CALML3 P27482 1/20 0.30
SDHA P31040 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3038249 0.90 MAOA (0.48) MAOAF10MAPTMAOBCALML3
SCHEMBL3043275 0.86 MAOA (0.43) MAOAGRIN1GRIN2BF10MAPT
SCHEMBL3039818 0.83 MAOA (0.38) MAOAGRIN1GRIN2BF10MAPT
SCHEMBL3035116 0.81 MAOA (0.38) MAOAGRIN1GRIN2BF10MAOB
SCHEMBL3038838 0.81 MAOA (0.43) MAOAF10MAPTNPC1RAB9A
SCHEMBL3045247 0.81 MAOA (0.41) MAOAGRIN1GRIN2BF10MAPT
SCHEMBL3038551 0.81 MAOA (0.37) MAOAGRIN1GRIN2BF10MAPT
SCHEMBL3041760 0.79 F10 (0.41) MAOAF10MAPTNPC1RAB9A
SCHEMBL3038429 0.79 MAOA (0.41) MAOAGRIN1GRIN2BF10MAOB
SCHEMBL3032006 0.75 MAOA (0.41) MAOAGRIN1GRIN2BF10MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY 2004-07-29 US claimed
US-7645781-B2 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PFIZER INC (US) 2010-01-12 US disclosed
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives THOMAS RICHARD C 2007-01-18 US disclosed
US-7141588-B2 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PFIZER, INC. (US) 2006-11-28 US disclosed
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY 2004-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 MAOA 957/4885GRIN1 1767/4885GRIN2B 888/4885
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 MAOA 957/4885GRIN1 1767/4885GRIN2B 888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.